Phase Ib Study: Lenvatinib + Pembrolizumab in Unresectable Hepatocellular Carcinoma

June 1-5, 2018; Chicago, Illinois
Lenvatinib combined with pembrolizumab showed promising antitumor activity with no unexpected toxicities in this early-stage study.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: June 7, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on best practices for molecular testing of targetable biomarkers in advanced NSCLC (May 2022), from Clinical Care Options (CCO)

Released: May 24, 2022

Gain expert pharmacist insight on the management of hemophilia A with factor and nonfactor replacement therapies

person default Justin Arnall, PharmD, BCOP person default Kayla Douglas, PharmD Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 24, 2022 Expired: May 23, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings